1-(Benzenesulfonyl)Pyrrole

Regioselective functionalization at the pyrrole C3 position, critical for the construction of 1,3,4-trisubstituted architectures found in a cluster of ATP-competitive kinase inhibitors, relies on the transient N-sulfonyl blocking strategy offered by 1-(benzenesulfonyl)pyrrole. In a representative kilo-lab campaign contracted for a Phase II clinical candidate, a 200 L glass-lined reactor equipped with a 15 kW silicon oil circulation thermostat and pitched-blade turbine agitator is charged with 1.0 kmol of the pyrrole dissolved in pre-dried tetrahydrofuran (THF) exhibiting Karl Fischer moisture below 50 ppm. The batch is cooled under a nitrogen sweep to an internal jacket setpoint of -82 °C to achieve a stable bulk temperature of -78 °C (±2 °C). A 1.05 molar equivalent of lithium diisopropylamide (LDA) as a 2.0 M solution in heptane/THF is metered via a PTFE diaphragm pump over 90–120 min such that the internal exotherm never exceeds -65 °C; excursions above that threshold promote ortho-directed metalation on the benzenesulfonyl ring, a side pathway that generates a desulfonylated impurity detectable at 0.5–3.2% by UPLC at 254 nm. Conversely, localized supercooling below -80 °C precipitates the N-lithiated intermediate as a sticky agglomerate that increases stirrer shaft deflection and triggers mechanical safety interlocks. After a 45 min age period, the electrophile—typically trimethyl borate for borylation, an alkyl chloroformate, or a nitrogen-transfer reagent—is introduced through a 1/4″ 316L dip tube at a rate controlled to limit the instantaneous temperature gradient to 2 °C/min maximum. The quench employs 30 wt% aqueous ammonium chloride pre-chilled to 5 °C, fed rapidly through a full-port ball valve to prevent localized pH rises that would hydrolyze the sulfonamide prematurely. Phase separation is performed in a coil coalescer with a 0.5 bar differential pressure to handle emulsions that occasionally form when the boronate ester is present. The organic layer is concentrated in a wiped-film evaporator at 45 °C / 50 mbar and the crude residue is crystallized from methylcyclohexane/toluene (4:1 v/v) using a 2 °C/min linear cooling ramp. Isolated yields typically reach 82–88% with HPLC purity (area normalization at 220 nm) of ≥99.0%, a single unknown impurity ≤ 0.10%, and residual palladium ≤ 5 ppm as measured by ICP-MS after microwave digestion in accordance with ICH Q3D Elemental Impurities Guideline for oral solid dosage forms. The 3-functionalized intermediate is released for subsequent sulfonamide cleavage or carbon–carbon bond formation under a Type II drug master file conforming to 21 CFR Part 210/211, with a full analytical dossier prepared per ICH M4Q Common Technical Document, including residual solvent headspace results versus USP <467>, identity by ¹H NMR (400 MHz) and ¹³C NMR (100 MHz), and trace metals profile screened against the ICH Q3C options table. The final drug substances—dominated by pyrimidine- and pyrazine-fused pyrrole scaffolds with IC₅₀ values in the low nanomolar range against targets such as EGFR-T790M or BTK—benefit directly from the ability to install a C3-aryl or C3-heteroaryl group with a regiochemical fidelity exceeding 98:2.

What Drives Regioselective Bromination at C4 for GABA-Gated Chloride Channel Probes?

In the manufacturing sequence for commercial acaricide–insecticide active ingredients that act as chloride channel activators, 1-(benzenesulfonyl)pyrrole is the scaffold onto which a precise halogenation pattern is imposed before cyanation and ultimate deprotection. The process initiates with exhaustive bromination: neat bromine (2.05 eq) is added subsurface to a solution of the pyrrole in glacial acetic acid maintained at 10–15 °C in a 500 L glass-lined reactor with external cuprous brine cooling. The addition rate is capped at 0.8 kg Br₂/min to keep the headspace bromine vapor concentration below 0.1 ppm as monitored by a continuous electrochemical sensor, and the batch is aged under darkness for 18 h to suppress photolytic radical substitution on the phenylsulfonyl moiety. The resultant 2,3,4,5-tetrabromo-1-(benzenesulfonyl)pyrrole is isolated by drowning into ice water and filtration; its median particle size of 45 μm after drying determines the kinetics of the subsequent selective debromination. That downstream step uses zinc dust (325 mesh) in 3:1 v/v ethanol/water at reflux to cleave the C2-bromine while leaving the C4- and C5-bromine intact. A persistent production bottleneck arises from the tendency of zinc fines to aggregate in the conventional turbine-agitated vessel, causing debromination rate scatter that shifts the residual monobromo-desulfonamide by-product from 1.5% to 6% area between batches when agitation drops below 80 rpm. Mitigation involves retrofitting the reactor with a high-shear rotor-stator assembly (3000 rpm) in the recirculation loop, which yields a metastable suspension and compresses reaction time from 6 h to 3.5 h with 94–96% regionselectivity. The 3,4-dibromo-1-(benzenesulfonyl)pyrrole intermediate is subjected to copper(I) cyanide substitution in NMP at 160 °C under rigorous anhydrous conditions (≤20 ppm water) to afford the bis-nitrile. Sulfonamide cleavage with 15 wt% aqueous sodium hydroxide in methanol at 50 °C releases the unprotected 3,4-dicyanopyrrole, which is extracted with methyl tert-butyl ether and sublimed at 120 °C/0.1 mbar to a purity ≥99.5%. Off-gases containing hydrogen cyanide are scrubbed through a packed column with 10% sodium hypochlorite solution; the integrated engineering controls must maintain time-weighted average HCN exposure below 4.7 ppm per OSHA 29 CFR 1910.1000. The resulting pesticide technical concentrate is analyzed for bromine carryover by ion chromatography per ASTM D4327-17 (acceptance criterion: ≤ 10 ppm) and registered with a five-batch analysis supporting FAO Specification 243/SC for chlorfenapyr-type activity. Formulation into a 240 g/L suspension concentrate requires the active ingredient to pass a wet-sieve residue test (75 μm, ≤ 0.1%). Transport is in UN-certified 4G fibreboard drums with LDPE inner liner, placarded with acute toxicity Category 3 pictograms reflecting an oral LD₅₀ (rat) of <300 mg/kg.

For fabricating electrochromic windows and corrosion-resistant coatings with a time-constant oxidation potential window of +0.8 to +1.2 V vs Ag/AgCl, poly(pyrrole) thin films electrodeposited onto ITO, platinum mesh, or mild steel require a monomer feedstock devoid of oligomeric seeds that act as uncontrolled nucleation sites. 1-(Benzenesulfonyl)pyrrole provides a crystalline, air-stable masked monomer isolable with a sharp melting point of 87–89 °C; it can be refined in a continuous wiped-film molecular still at 140 °C and 0.005 mbar to reduce transition-metal quenchers to Cu <1 ppb and Fe <2 ppb by ICP-MS per ISO 11885:2007. The purified solid is melted under argon and delivered through heated jacketed tubing (90 °C) to a nitrogen-capped dispersion vessel containing acetonitrile and 0.1 M tetrabutylammonium hexafluorophosphate. After stoichiometric deprotection with methanolic sodium methoxide (1.2 eq, 25 °C, 30 min), the solution is filtered through a 0.2 μm PTFE capsule and introduced directly into a three-electrode flow cell. Deposition at a constant current density of 1.0 mA/cm² yields films with root-mean-square roughness ≤ 5 nm by AFM and a conductivity of 15–25 S/cm after doping with p-toluenesulfonate. The commercial monomer for this segment is supplied with a trace aldehyde and ketone specification ≤ 0.05% each, since these carbonyl impurities quench the propagating radical-cation chain and raise the polydispersity index above 2.5 in the final polymer batch.

When Acetylenedicarboxylate Dienophiles Are Met by Benzenesulfonyl Pyrrole in a Diels–Alder Regime

[4+2] Cycloaddition between N-benzenesulfonyl pyrrole and acetylenic dienophiles constitutes a concise route to nitrogen-containing bicyclo[2.2.1] frameworks that, upon reduction, yield tropane alkaloid precursors or constrained piperidine building blocks for central nervous system drug candidates. Because the diene character of the pyrrole nucleus is partially attenuated by the electron-withdrawing sulfonamide, elevated pressure becomes a necessary kinetic enabler in multi-purpose API suites. A campaign executed in a 63 L Hastelloy C276 stirred autoclave rated for 100 bar at 200 °C demonstrates the operating envelope: the substrate (1.0 eq) is dissolved in dichloromethane together with dimethyl acetylenedicarboxylate (1.4 eq), charged into the vessel, and pressurized with zero-air to 45 bar at 22 °C before heating to a jacket temperature of 80 °C. The internal pressure stabilizes at 52–55 bar during the 8 h hold; a burst-disc relief path sized per ISO 4126-1 vents into a rupture basin designed for a 200 L adiabatic runaway scenario. After controlled depressurization, the bicyclic adduct is concentrated in a short-path evaporator and subjected to sulfonamide cleavage using 6 N HCl in isopropanol at 60 °C, which liberates the free amine while the benzenesulfinic acid by-product is captured by an Amberlyst A21 weak-base resin column to keep chloride salt contamination of the next intermediate below 0.2%. The deprotected 7-azabicyclo[2.2.1]heptane scaffold is then hydrogenated over 5% Rh/C in MTBE at 4 bar hydrogen, affording the N-Boc-protected tropane analogue isolated as its hydrochloride salt with a chemical purity of 99.3% by qNMR. The multi-step sequence operates within a manufacturing facility certified under the ISO 14001 environmental management standard; solvent recovery via integrated rectification columns keeps total VOC emissions below 50 kg/metric ton of product. For regulatory filing, the intermediate is designated a Registered Starting Material per ICH Q11, with critical quality attributes including chiral purity (enantiomeric excess ≥99.5%) determined by SFC on a Chiralpak IA-3 column.

Scalable Reductive Detosylation and Pyrrolidine Ring Saturation in Chiral Intermediate Streams

Downstream functionalization of the C3-substituted N-benzenesulfonyl pyrrole intermediates to chirally pure pyrrolidine synthons—key sp³-rich fragments in dipeptidyl peptidase-4 (DPP-4) inhibitors and other metabolic disorder targets—demands a two-stage hydrogenation protocol that simultaneously cleaves the sulfonamide and saturates the heterocycle. The substrate (1.0 eq) is dissolved in absolute ethanol with 5% palladium on carbon (type 39, water content 50%) loaded at 8 wt% relative to substrate, and treated with ammonium formate (4.0 eq) as a transfer hydrogenolysis agent in a 50 L pressure-rated vessel with a magnetically coupled agitator. The headspace is purged five times with nitrogen before introducing hydrogen at a regulated pressure of 8 bar; the exotherm is managed by a recirculating chiller maintaining an internal temperature of 25 °C ± 3 °C. Monitoring by in-situ FTIR at 1350 cm⁻¹ for the sulfonamide S=O asymmetric stretch tracks conversion to the N-unsubstituted pyrrole, which auto-hydrogenates under the same conditions to form racemic pyrrolidine. To drive stereochemical outcome, the addition of a Julia-Kocienski-type chiral sulfinamide after detosylation, or the direct asymmetric hydrogenation employing a Ru-BINAP catalyst in methanol at 50 bar H₂ and 60 °C, installs the desired (R) or (S) configuration at C2 with an enantiomeric ratio of 96:4. Residual palladium in the isolated pyrrolidine hydrochloride salt is scavenged through a functionalized thiol silica cartridge to levels below 10 ppm, measured by ICP-OES per EN 15763. The final chiral amine is specified with specific optical rotation ([α]_D²⁰ +18.5° ± 1°, c = 1.0, methanol) and a 10% loss on drying by TGA under nitrogen. Process robustness studies identified nickel leaching from older storage vessels as a root cause of unexpected debenzylation profiles during hydrogenolysis; converting from 304 stainless steel to electropolished 316L for all transfer lines downstream of the hydrogenation skid eliminated batch-to-batch absorbance at 280 nm indicative of dissolved metal interference. The overall manufacturing route for the pyrrolidine intermediate is supported by a risk assessment for potential N-nitrosamine formation, quantifying N-Nitrosopyrrolidine below the 26.5 ng/day acceptable intake limit by LC-MS/MS, consistent with EMA/449136/2019 guidelines, with reactive amine quenchers built into the work-up sequence.

Beyond dedicated synthetic routes, 1-(benzenesulfonyl)pyrrole is inventoried as a portfolio-grade building block in contract development and manufacturing organizations, normally stocked in three purity grades that map to clearly demarcated end-use categories. The warehouse specification system distinguishes technical grade (minimum 97.0% GC purity, used for agrochemical and materials screening), pharmaceutical grade (≥99.0% HPLC, water ≤ 0.1%, sulfone dimer ≤ 0.15%, packaged under argon in fluorinated HDPE drums for API intermediate service), and electronic grade (≥99.95% assay, metal ion ensemble ≤ 500 ppb, supplied in quartz-lined containers with Teflon-overmolded caps for organic electronics applications). Certificates of analysis for pharmaceutical grade align with the European Pharmacopoeia monograph criteria for related substances (impurity A, B, C reporting thresholds at 0.05%) and include a shelf-life statement validated by a 36-month real-time stability study at 25 °C/60% RH in a climate-controlled chamber per ICH Q1A(R2). Handling hazards are governed by safety data sheets conforming to GHS Rev. 9: the solid exhibits skin sensitization Category 1B and requires a full-face air-purifying respirator with combination organic vapor/HEPA cartridges during sampling. Incompatibility with strong oxidizing agents and acetyl chloride is documented; calorimetric screening by differential scanning calorimetry identifies an exothermic onset at 295 °C (387 J/g), placing it outside the immediate “bomb” hazard zone but requiring that bulk storage silos be fitted with a temperature watch system set to alarm at 60 °C. For international multi-modal logistics, the correct shipping description is UN 3077, Environmentally Hazardous Substance, Solid, N.O.S., Packing Group III for sea freight, with a customs tariff code harmonized under 2933.99 for heterocyclic compounds containing an unfused pyrrole ring. A comparison of the key attributes across the commercial grades can assist formulation chemists and supply-chain managers in selecting the most cost-appropriate specification without over-processing.